Just caught wind that X4 Pharma got a positive opinion from the European Medicines Agency for mavorixafor treating WHIM syndrome - pretty solid news on a Friday like this. Rare immunodeficiency disorder, so it's a niche market but these approvals usually move the needle for biotech stocks. The Phase 3 trial results backed it up, which is the main thing investors care about. They've already locked in a deal with Norgine back in January to handle commercialization across Europe, Australia and New Zealand, so the infrastructure's in place. Looking at the numbers, X4 could pocket up to $226 million from hitting various regulatory and sales milestones, plus they're getting royalties that could hit the mid-20s percentage range on net sales. European Commission decision is expected sometime in Q2 2026, so probably coming soon. Stock was trading around $3.25 earlier, down a bit, but regulatory wins like this usually get priced in over time. Curious to see how the market reacts once the formal EC approval comes through - these rare disease approvals tend to create some positive momentum for smaller pharma plays.